RT Journal Article
SR Electronic
T1 Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation.
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 948
OP 950
DO 10.1136/jcp.41.9.948
VO 41
IS 9
A1 S Mackinnon
A1 A K Burnett
A1 R J Crawford
A1 S Cameron
A1 B G Leask
A1 R G Sommerville
YR 1988
UL http://jcp.bmj.com/content/41/9/948.abstract
AB Seventy one patients underwent bone marrow transplantation for aplastic anaemia or haematological malignancy, 39 as allografts and 32 as autografts. All patients who were seronegative to cytomegalovirus received blood product support exclusively from seronegative community blood donors; seropositive patients received unscreened products. In no patients was there any attempt to reduce cytomegalovirus (CMV) infection by giving prophylaxis with immunoglobulin, and granulocyte transfusions were not given. The incidence of cytomegalovirus infection in the seronegative recipients (22 allograft, 15 autograft) was 0%; in the seropositive recipients 16 (63%) in allografts and 17 (18%) in autografts. These results suggest that provision of exclusively seronegative blood products is an important contribution for seronegative transplant recipients, but make little impact in autologous transplantation where the incidence of infection is low.